Income statement
USD
Annual
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | 6M | 3M |
| Gross Profit | 5M | 3M |
| Operating Income | 4M | 3M |
| EBITDA | 4M | 3M |
| Net Income | 2M | 1M |
| EPS (Diluted) | — | — |
Healthcare
Live Price
Offline$0.06
-0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stemcell Holdings, Inc. (STMM) is a Healthcare stock with a market cap of $1.64M and listed on OTC. The stock last traded around $0.06 and up 0.0% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +85.1%, EPS growth of +71.9%, a dividend yield of 0.0%. What stands out right now is revenue +85.1%, EPS +71.9%, free cash flow -31.7% with operating margin 58.3% and ROIC 63.3%. Valuation is more restrained than many high-expectation growth names at P/E 0.7 and price/sales 0.3. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines STMM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STMM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STMM Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STMM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.3M
-46.0% YoY
FY Net Income
$1.4M
-41.8% YoY
Free Cash Flow
$2.8M
+46.4% YoY
Revenue Growth
+85.1%
EPS Growth
+71.9%
Gross Margin
80.8%
Net Margin
39.0%
Income statement
USD
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | 6M | 3M |
| Gross Profit | 5M | 3M |
| Operating Income | 4M | 3M |
| EBITDA | 4M | 3M |
| Net Income | 2M | 1M |
| EPS (Diluted) | — | — |
Balance sheet
USD
| Metric | 2017 | 2016 | 2015 |
|---|---|---|---|
| Cash & Equivalents | 4M | 3M | 0 |
| Total Assets | 6M | 3M | 0 |
| Total Liabilities | 3M | 2M | 3K |
| Shareholder Equity | 4M | 1M | -3K |
| Total Debt | 0 | 43K | 0 |
| Net Debt | -4M | -3M | 0 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+33.4% YoY
Capital Expenditures
601K
+5.2% YoY
Free Cash Flow
3M
+46.4% YoY
Key ratios
Gross Margin
80.8%
Operating Margin
58.3%
Net Margin
39.0%
ROE
93.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.